Cadrenal Therapeutics announces 1-for-15 reverse stock split effective Aug 20, 2024

Cadrenal Therapeutics, Inc.

Reverse stock split ratio set at 1-for-15; effective at 12:01 a.m. ET on August 20, 2024.
Outstanding shares reduced from ~16M to ~1.1M; no fractional shares; cash paid in lieu.
New CUSIP number 127636 207; stock continues trading under CVKD on Nasdaq.
Split intended to regain compliance with Nasdaq minimum $1.00 bid price requirement.
Proportional adjustments made to equity awards, warrants, and exercise prices.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.